Microbot Medical Partners With Baptist Hospital of Miami to Participate in Its Pivotal Human Clinical Trial
Microbot Medical Partners With Baptist Hospital of Miami to Participate in Its Pivotal Human Clinical Trial
Following the Company's recent FDA approval to commence its pivotal human clinical trial, Baptist Hospital of Miami is the second clinical site to enroll in the trial
在該公司最近獲得FDA批准開展關鍵的人體臨床試驗之後，邁阿密浸信會醫院成爲第二個參與試驗的臨床地點。
BRAINTREE, Mass., July 03, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY Endovascular Robotic Surgical System, today announces it has received Institutional Review Board approval and signed a Clinical Trial Agreement with Baptist Hospital of Miami, which includes Miami Cardiac & Vascular Institute and Miami Cancer Institute. This is the second announced site that will participate in the clinical trial for Microbot's LIBERTY as part of its Investigational Device Exemption ("IDE"). The Company had recently announced Brigham and Women's Hospital as another participating site.
2024年7月3日，Microbot Medical Inc. (納斯達克代碼：MBOT)的創新性LIBERTY內窺鏡機器人手術系統開發商宣佈，已獲得機構審查委員會的批准並簽署了與邁阿密浸信會醫院（包括邁阿密心臟和血管研究所和邁阿密癌症研究所）的臨床試驗協議。這是第二個參與Microbot的LIBERTY臨床試驗的機構。該公司最近還宣佈布里格姆婦女醫院是另一個參與機構。
The principal investigator at Baptist Hospital of Miami will be Ripal Gandhi, MD, FSVM. "I am very excited to participate in the trial. I believe this technology has the potential to change how we perform endovascular procedures," said Dr. Gandhi.
“我們相信對自由技術的興趣是壓倒性的，正如我們宣佈IDE以來快速招募和激活領先的試驗站點所證明的那樣。我們很高興與邁阿密浸會醫院的合作，這是美國領先的醫院之一。”Microbot Medical的CEO，總裁和主席Harel Gadot評論道。
"We believe the interest in the LIBERTY technology is overwhelming, as evident by the fast pace of enrolling and activating leading sites into the pivotal trial since we announced the IDE. We are excited for our partnership with Baptist Hospital of Miami, which is one of the leading hospitals in the United States," commented Harel Gadot, CEO, President and Chairman of Microbot Medical.
Microbot Medical Inc.（納斯達克股票代碼：MBOT）是一家專注於轉型微機器人技術的臨床醫療器械公司，旨在通過人體內部的自然和人造腔道改善患者的臨床結果和增加可訪問性。
About Microbot Medical
關於Microbot Medical
Microbot Medical Inc. (NASDAQ: MBOT) is a clinical- stage medical device company that specializes in transformational micro-robotic technologies, with the goals of improving clinical outcomes for patients and increasing accessibility through the natural and artificial lumens within the human body.
Microbot Medical Inc.（納斯達克：MBOT）是一家臨床醫療器械公司，專注於改善患者的臨床預後和通過人體內自然和人工管腔提高醫療設備的易用性。
The Investigational LIBERTY Endovascular Robotic Surgical System aims to improve the way surgical robotics are being used in endovascular procedures today, by eliminating the need for large, cumbersome, and expensive capital equipment, while reducing radiation exposure and physician strain. The Company believes the LIBERTY Endovascular Robotic Surgical System's remote operation has the potential to be the first system to democratize endovascular interventional procedures.
探索一種改進內窺鏡手術機器人在內窺鏡治療中的使用方式，Microbot Medical研發的LIBERTY內窺鏡手術機器人系統能夠消除大型、笨重且昂貴的設備，減少放射線暴露和醫生的壓力。該公司認爲，LIBERTY內窺鏡手術機器人系統的遠程操作有可能成爲第一個民主化內窺鏡介入手術的系統。
Further information about Microbot Medical is available at .
有關Microbot Medical的更多信息，請訪問 。
Safe Harbor
免責聲明
Statements to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects" and "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, market conditions, risks inherent in the development and/or commercialization of the LIBERTY Endovascular Robotic Surgical System, the outcome of its studies to evaluate the LIBERTY Endovascular Robotic Surgical System, uncertainty in the results of pre-clinical and clinical trials or regulatory pathways and regulatory approvals, including whether the Company's pivotal study in humans is successful, any failure or inability to recruit physicians and clinicians to serve as primary investigators to conduct regulatory studies which could adversely affect or delay such studies, disruptions resulting from new and ongoing hostilities between Israel and the Palestinians and other neighboring countries, any lingering uncertainty resulting from the COVID-19 pandemic, need and ability to obtain future capital, and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical can be found under the heading "Risk Factors" in Microbot Medical's periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC's web site at www.sec.gov. Microbot Medical disclaims any intent or obligation to update these forward-looking statements, except as required by law.
對未來財務和/或運營結果、研究、技術、臨床開發的未來增長以及Microbot Medical Inc.及其子公司的潛在機會等作出的陳述，以及管理層對未來預期、信念、目標、計劃或前景的其他陳述，均構成《1995年私人證券訴訟改革法》和聯邦證券法的前瞻性陳述。任何不是歷史事實的陳述（包括但不限於包含單詞 "將"、"相信"、"計劃"、"預期" 和 "估計" 的陳述）也應被視爲前瞻性陳述。前瞻性陳述涉及風險和不確定性，包括但不限於市場狀況，開發和/或商業化LIBERTY內窺鏡機器人手術系統的固有風險，其評估LIBERTY內窺鏡機器人手術系統的研究結果的不確定性，以及臨床試驗或監管途徑和監管批准的不確定性，包括公司的人體關鍵研究是否成功，在招募醫生和臨床醫生擔任主要研究者方面可能發生的任何失敗或無法招募，可能會不利影響或延遲這些研究，新近以色列和巴勒斯坦以及其他鄰國之間的敵對態度，由於COVID-19大流行，任何仍存的不確定性，未來需要和能力獲得資本，以及維護知識產權的需求和能力。有關Microbot Medical面臨的風險的其他信息，請參見Microbot Medical在證券交易委員會（SEC）提交的定期報告中的"風險因素" 標題下的相關內容，可在SEC的網站www.sec.gov上獲得。Microbot Medical概不承擔更新這些前瞻性陳述的義務或責任，除非法律有要求。
Investor Contact:
投資者聯繫：
Michal Efraty
米哈爾·埃夫拉蒂
IR@microbotmedical.com
IR@microbotmedical.com
Source: Microbot Medical Inc.
來源：微型機器人醫療公司
譯文內容由第三人軟體翻譯。